PT1801209E - Arn gen?mico do v?rus humano modificado da hepatite c com capacidade de replica??o aut?noma - Google Patents

Arn gen?mico do v?rus humano modificado da hepatite c com capacidade de replica??o aut?noma Download PDF

Info

Publication number
PT1801209E
PT1801209E PT05781421T PT05781421T PT1801209E PT 1801209 E PT1801209 E PT 1801209E PT 05781421 T PT05781421 T PT 05781421T PT 05781421 T PT05781421 T PT 05781421T PT 1801209 E PT1801209 E PT 1801209E
Authority
PT
Portugal
Prior art keywords
coding sequence
protein coding
genomic rna
virus genomic
hepatitis
Prior art date
Application number
PT05781421T
Other languages
English (en)
Inventor
Takaji Wakita
Takanobu Kato
Tomoko Date
Michiko Miyamoto
Ralf Bartenschlager
Jun-Ichi Tanabe
Saburo Sone
Original Assignee
Toray Industries
Tokyo Metropolitan Org Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Tokyo Metropolitan Org Med Res filed Critical Toray Industries
Publication of PT1801209E publication Critical patent/PT1801209E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT05781421T 2004-08-24 2005-08-24 Arn gen?mico do v?rus humano modificado da hepatite c com capacidade de replica??o aut?noma PT1801209E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004243975 2004-08-24
JP2004290801 2004-10-01
JP2005069527 2005-03-11
JP2005069725 2005-03-11

Publications (1)

Publication Number Publication Date
PT1801209E true PT1801209E (pt) 2011-05-26

Family

ID=35967617

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05781421T PT1801209E (pt) 2004-08-24 2005-08-24 Arn gen?mico do v?rus humano modificado da hepatite c com capacidade de replica??o aut?noma

Country Status (13)

Country Link
US (2) US8454973B2 (pt)
EP (1) EP1801209B1 (pt)
JP (1) JP4931591B2 (pt)
KR (1) KR101262773B1 (pt)
CN (1) CN101048502B (pt)
AT (1) ATE499442T1 (pt)
AU (1) AU2005275713B2 (pt)
CA (1) CA2578021C (pt)
DE (1) DE602005026545D1 (pt)
HK (1) HK1112481A1 (pt)
PL (1) PL1801209T3 (pt)
PT (1) PT1801209E (pt)
WO (1) WO2006022422A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1794183A2 (en) * 2004-10-01 2007-06-13 Novartis Vaccines and Diagnostics S.r.l. Hepatitis c virus replication system
WO2006096459A2 (en) 2005-03-04 2006-09-14 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
US8364417B2 (en) 2007-02-15 2013-01-29 454 Life Sciences Corporation System and method to correct out of phase errors in DNA sequencing data by use of a recursive algorithm
US8301394B2 (en) * 2006-02-16 2012-10-30 454 Life Sciences Corporation System and method for correcting primer extension errors in nucleic acid sequence data
JP2008161080A (ja) * 2006-12-27 2008-07-17 Japan Health Science Foundation Ｃ型肝炎ウイルス阻害剤を検出するためのアッセイ方法
US8454974B2 (en) 2007-04-13 2013-06-04 Hvidovre Hospital Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A
US8945584B2 (en) 2007-04-13 2015-02-03 Hvidovre Hospital Cell culture system of a hepatitis C genotype 3a and 2a chimera
JPWO2008136470A1 (ja) * 2007-04-27 2010-07-29 株式会社先端生命科学研究所 Ｈｃｖ遺伝子
WO2008141651A1 (en) 2007-05-18 2008-11-27 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 5a
EP2186893A4 (en) * 2007-07-13 2010-10-20 Jp Nat Inst Infectious Disease PREPARATION AND USE OF A EPITOPEAGED HEPATITIS C VIRUS PARTICLE
JPWO2009014216A1 (ja) * 2007-07-25 2010-10-07 国立感染症研究所長 Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体およびその用途
WO2009080052A1 (en) 2007-12-20 2009-07-02 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 6a
EP2235164A1 (en) 2007-12-20 2010-10-06 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 1a and 1b
WO2009131203A1 (ja) 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸
WO2010017818A1 (en) 2008-08-15 2010-02-18 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 2b
WO2010017819A1 (en) 2008-08-15 2010-02-18 Hvidovre Hospital EFFICIENT CELL CULTURE SYSTEM FOR HEPATITIS C VIRUS GENOTYPE 7a
US8993228B2 (en) 2008-09-30 2015-03-31 Toray Industries, Inc. Antibody binding to envelope protein 2 of hepatitis C virus and method for identifying genotype of hepatitis C virus using the same
EP2344647A1 (en) 2008-10-03 2011-07-20 Hvidovre Hospital Hepatitis c virus expressing reporter tagged ns5a protein
JP5692738B2 (ja) * 2009-07-28 2015-04-01 国立大学法人 鹿児島大学 ウイルスの濃縮方法および磁性体組成物
CN102596244A (zh) 2009-09-30 2012-07-18 东丽株式会社 丙型肝炎病毒疫苗组合物
CA2778568A1 (en) 2009-10-30 2011-05-05 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis c virus (hcv) infection and use thereof
WO2011156707A2 (en) 2010-06-11 2011-12-15 Life Technologies Corporation Alternative nucleotide flows in sequencing-by-synthesis methods
AU2011313158B2 (en) * 2010-10-08 2014-09-25 Advanced Life Science Institute, Inc. Hepatitis C virus gene
US10273540B2 (en) 2010-10-27 2019-04-30 Life Technologies Corporation Methods and apparatuses for estimating parameters in a predictive model for use in sequencing-by-synthesis
EP2633470B1 (en) 2010-10-27 2016-10-26 Life Technologies Corporation Predictive model for use in sequencing-by-synthesis
EP2659408B1 (en) 2010-12-29 2019-03-27 Life Technologies Corporation Time-warped background signal for sequencing-by-synthesis operations
WO2012092515A2 (en) 2010-12-30 2012-07-05 Life Technologies Corporation Methods, systems, and computer readable media for nucleic acid sequencing
US10146906B2 (en) 2010-12-30 2018-12-04 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
US20130060482A1 (en) 2010-12-30 2013-03-07 Life Technologies Corporation Methods, systems, and computer readable media for making base calls in nucleic acid sequencing
JPWO2012133735A1 (ja) 2011-03-31 2014-07-28 国立感染症研究所長 遺伝子型１ｂのＣ型肝炎ウイルスゲノム由来の核酸を含む核酸構築物、及び該核酸構築物が導入されたＣ型肝炎ウイルスゲノム複製細胞、並びに感染性Ｃ型肝炎ウイルス粒子の製造方法
CN103764845B (zh) 2011-04-08 2016-02-17 生命科技股份有限公司 用于合成测序中的相保护试剂流排序
US9186383B2 (en) 2011-05-31 2015-11-17 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Mutant replicon derived from genome of hepatitis C virus J6CF strain
US10704164B2 (en) 2011-08-31 2020-07-07 Life Technologies Corporation Methods, systems, computer readable media, and kits for sample identification
WO2013031956A1 (ja) 2011-08-31 2013-03-07 国立感染症研究所長が代表する日本国 遺伝子型３aのＣ型肝炎ウイルスゲノム由来の核酸を含む核酸構築物
CA2863282A1 (en) * 2012-01-13 2013-07-18 Gilead Pharmasset Llc Crystal structure of hcv polymerase complexes and methods of use
US9646132B2 (en) 2012-05-11 2017-05-09 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
US10329608B2 (en) 2012-10-10 2019-06-25 Life Technologies Corporation Methods, systems, and computer readable media for repeat sequencing
US20140296080A1 (en) 2013-03-14 2014-10-02 Life Technologies Corporation Methods, Systems, and Computer Readable Media for Evaluating Variant Likelihood
US9926597B2 (en) 2013-07-26 2018-03-27 Life Technologies Corporation Control nucleic acid sequences for use in sequencing-by-synthesis and methods for designing the same
EP3053072B1 (en) 2013-10-04 2024-02-21 Life Technologies Corporation Methods and systems for modeling phasing effects in sequencing using termination chemistry
US10676787B2 (en) 2014-10-13 2020-06-09 Life Technologies Corporation Methods, systems, and computer-readable media for accelerated base calling
EP3295345B1 (en) 2015-05-14 2023-01-25 Life Technologies Corporation Barcode sequences, and related systems and methods
US10619205B2 (en) 2016-05-06 2020-04-14 Life Technologies Corporation Combinatorial barcode sequences, and related systems and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
DE60034884T2 (de) * 1999-06-04 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
DK1233782T3 (da) 1999-12-01 2009-02-09 Novartis Vaccines & Diagnostic Fremkaldelse af HCV-specifikke antistoffer
IL137522A (en) 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
JP4880116B2 (ja) * 2000-12-01 2012-02-22 財団法人 東京都医学総合研究所 劇症ｃ型肝炎ウイルス株の遺伝子
US20050250093A1 (en) 2002-04-03 2005-11-10 Gates Adam T Hepatitis c virus sub-genomic replicons
EP1627917B1 (en) 2003-05-26 2010-06-16 Toray Industries, Inc. NUCLEIC ACID CONSTRUCT CONTAINING HEPATITIS C VIRUS (HCV) OF GENOCYPE 2a GENOME-ORIGIN NUCLEIC ACID AND CELL HAVING THE NUCLEIC ACID CONSTRUCT TRANSFERRED THEREINTO
EP1794183A2 (en) * 2004-10-01 2007-06-13 Novartis Vaccines and Diagnostics S.r.l. Hepatitis c virus replication system
WO2006096459A2 (en) 2005-03-04 2006-09-14 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2009131203A1 (ja) * 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸

Also Published As

Publication number Publication date
HK1112481A1 (en) 2008-09-05
CN101048502B (zh) 2012-03-21
CA2578021A1 (en) 2006-03-02
AU2005275713B2 (en) 2010-08-05
US8454973B2 (en) 2013-06-04
CN101048502A (zh) 2007-10-03
EP1801209A1 (en) 2007-06-27
KR101262773B1 (ko) 2013-05-10
AU2005275713A1 (en) 2006-03-02
KR20070045333A (ko) 2007-05-02
ATE499442T1 (de) 2011-03-15
US20090176200A1 (en) 2009-07-09
DE602005026545D1 (de) 2011-04-07
WO2006022422A1 (ja) 2006-03-02
EP1801209A4 (en) 2007-12-05
CA2578021C (en) 2014-11-18
PL1801209T3 (pl) 2011-07-29
JPWO2006022422A1 (ja) 2008-05-08
JP4931591B2 (ja) 2012-05-16
EP1801209B1 (en) 2011-02-23
US9175269B2 (en) 2015-11-03
US20130115592A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
HK1112481A1 (en) Modified human hepatitis c virus genomic rna having autonomous replicative competence
Mandl et al. Spontaneous and engineered deletions in the 3′ noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
Jones et al. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus
Fan et al. The intrinsic disorder status of the human hepatitis C virus proteome
Ezelle et al. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
JP2008516610A5 (pt)
EP1930416A4 (en) NEW RECOMBINANT PARTICLE SIMILAR TO HUMAN HEPATITIS C VIRUS AND METHOD FOR THE MANUFACTURE THEREOF
HK1092498A1 (en) Composition containing the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
Naderi et al. Hepatitis C virus and vaccine development
Londono-Renteria et al. A brief review of West Nile virus biology
Tajima et al. Restoration of replication-defective dengue type 1 virus bearing mutations in the N-terminal cytoplasmic portion of NS4A by additional mutations in NS4B
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
Lattwein et al. Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3
Manickam et al. Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections
Bittar et al. Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response
Varshney et al. A review on an update of NS5B polymerase hepatitis C virus inhibitors
Sarwar et al. NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b
McElroy et al. Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes
WO2008136470A1 (ja) Ｈｃｖ遺伝子
WO2005032329A3 (en) Methods and compositions for identifying anti-hcv agents
Suzuki et al. Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b
EP3212775A1 (en) Optimized hcv full-length infectious cell culture systems and applications thereof
Chopra Characteristics of the hepatitis C virus